7:05 AM
Feb 15, 2019
 |  BC Extra  |  Company News

Keytruda-Inlyta combo under Priority Review for first-line RCC

Editor's Note: This article was updated on Feb 15, 2019 at 10:45 AM PST

Merck & Co. Inc. (NYSE:MRK) said FDA accepted and granted Priority Review to its sBLA for Keytruda pembrolizumab plus Inlyta axitinib as a first-line treatment for renal cell carcinoma. Its PDUFA date is June 20.

The sBLA includes data from the Phase III KEYNOTE-426 study, in which the...

Read the full 219 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >